Placebo-controlled trials in schizophrenia: Are they ethical? Are they necessary?

Schizophrenia Research

Volumn 35, Issue 3, 1999, Pages 211-218

  Weijer, Charles ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Clinical trials; Ethics; Placebo control; Research Methodology; Schizophrenia

Indexed keywords

CLINICAL PROTOCOL; CONFERENCE PAPER; DRUG RESEARCH; HUMAN; LEGAL LIABILITY; MEDICAL ETHICS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA;

BIOMEDICAL AND BEHAVIORAL RESEARCH; MENTAL HEALTH THERAPIES;

ANTIPSYCHOTIC AGENTS; CONTROLLED CLINICAL TRIALS; ETHICS, MEDICAL; HUMANS; PATIENT COMPLIANCE; RESEARCH DESIGN; SCHIZOPHRENIA;

EID: 0033558325     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00127-3     Document Type: Conference Paper

References (25)

1. Beecher H.K. Ethics and clinical research. New Engl. J. Med. 274:1966;1354-1360.
2. Blackwelder W.C. 'Proving the null hypothesis' in clinical trials. Control. Clin. Trials. 3:1982;345-353.
3. Carpenter W.T., Schooler N.R., Kane J.M. The rationale and ethics of medication free research in schizophrenia. Arch. Gen. Psychiatry. 54:1997;401-407.
4. Elliott C., Weijer C. Cruel and unusual treatment. Sat. Night. 110(10):1995;31-34.
5. Freedman B. Equipoise and the ethics of clinical research. New Engl. J. Med. 317:1987;141-145.
6. Freedman B. Placebo-controlled trials and the logic of clinical purpose. IRB: Rev. Hum. Subj. Res. 12(6):1990;1-6.
7. Freedman B., Glass K.C., Weijer C. Placebo orthodoxy in clinical research II: ethical, legal, and regulatory myths. J. Law Med. Ethics. 24:1996;252-259.
8. Freedman B., Weijer C., Glass K.C. Placebo orthodoxy in clinical research I: empirical and methodological myths. J. Law Med. Ethics. 24:1996;243-251.
9. Fuks A., Weijer C., Freedman B., Shapiro S., Skrutkowska M., Riaz A. A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. J. Clin. Epidemiol. 51:1998;69-79.
10. Henry D., Hill S. Comparing treatments: comparisons should be against active treatments rather than placebos. Br. Med. J. 310:1995;1279.
11. Kane J.M. Schizophrenia. New Engl. J. Med. 334:1996;34-41.
12. Katz J. Human sacrifice and human experimentation: reflections at Nuremberg. Yale J. Int. Law. 22:1997;401-418.
13. Lasagna L. The Helsinki Declaration: timeless guide or irrelevant anachronism? J. Clin. Psychopharmacol. 15:1995;96-98.
14. Makuch R., Simon R. Sample size requirements for evaluating conservative therapy. Cancer Treat. Rep. 62:1978;1037-1040.
15. Makuch R., Johnson M. Issues in planning and interpreting active control equivalence studies. J. Clin. Epidemiol. 42:1989;503-511.
16. Medical Research Council of Canada, 1987. Guidelines on Research Involving Human Subjects. Minister of Supply and Services, Ottawa.
17. Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada, 1998. Tri-Council Policy Statement on Ethical Conduct for Research Involving Humans. Minister of Supply and Services, Ottawa.
18. Office for Protection from Research Risk, 1993. Protecting Human Subjects: Institutional Review Board Guidebook. US Government Printing Office, Washington, DC.
19. Rahman Z.U., Frye D.K., Buzdar A.U., Smith T.L., Asmar L., Champlin R.E., Hortobagyi G.N. Impact of selection process on response rate and long term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J. Clin. Oncol. 15:1997;3171-3177.
20. Rothman K.J., Michels K.B. The continuing unethical use of placebo controls. New Engl. J. Med. 331:1994;394-398.
21. Temple R, 1982. Government viewpoint of clinical trials. Drug Info. J. (Jan./Feb.), 10-17.
22. Temple R., 1983. Difficulties in evaluating positive control trials. Proc. Am. Statist. Assoc., Biopharmaceutical Section: 1-7.
23. Temple R. Problems in interpreting active control equivalence trials. Accountability Res. 4:1996;267-275.
24. Weijer C., Appelbaum P. Placebo controls are not good science (letter to the editor and response). IRB: Rev. Hum. Subj. Res. 18(5):1996;8-10.
25. World Medical Association, 1995. Declaration of Helsinki [1964, rev. 1975, 1983, 1989]. In: Reich, W.T. (Ed.), Encyclopedia of Bioethics, rev. ed. Simon and Schuster/Macmillan, New York, pp. 2765-2767.